The novel bronchodilator navafenterol: a phase 2a, multi-centre, randomised, double-blind, placebo-controlled crossover trial in COPD.

Dave SinghJutta BeierCarol AstburyMaria G BelvisiCarla A Da SilvaAlexandra JauhiainenEulalia JimenezAlejhandra LeiSofia NecanderJaclyn Ann SmithUlrika Wählby HamrénWenjing XinIoannis Psallidas

Published in: The European respiratory journal (2021)

Once-daily navafenterol was well tolerated, improved lung function and reduced COPD-related symptoms, similar to an established once-daily fixed-dose combination bronchodilator.

Keyphrases

lung function
placebo controlled
double blind
phase iii
phase ii
study protocol
chronic obstructive pulmonary disease
clinical trial
cystic fibrosis
air pollution
physical activity
phase ii study
open label
randomized controlled trial
sleep quality
drug induced
radiation therapy